TransMedics director exercises options, sells shares

TransMedics Group director Thomas J. Gunderson exercised stock options to acquire 19,285 shares of common stock at an exercise price of $2.21 per share on June 15, 2026.

Rhea-AI Filing Summary

TransMedics Group director Thomas J. Gunderson exercised stock options to acquire 19,285 shares of common stock at an exercise price of $2.21 per share on June 15, 2026. On the same date he sold 9,624 shares at $75.06 per share, and after these transactions he directly holds 16,642 common shares. A contextual note states that shares sold were used to cover the option exercise price and related tax withholding obligations.

Insights

Equity compensation and insider-trading analyst

Routine option exercise with partial sale mainly to cover costs.

Director Thomas J. Gunderson exercised stock options for 19,285 TransMedics shares at $2.21 and sold 9,624 shares at $75.06. Footnotes state the sale was used to cover the option exercise price and related tax withholding obligations.

This pattern is typical of equity compensation events, where insiders monetize a portion of newly acquired shares to handle cash costs rather than making a discretionary portfolio decision. Following the transactions, Gunderson holds 26,266 shares directly, indicating a net increase in his equity exposure from this grant.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Gunderson Thomas J.

Role Director

Sold 9,624 shs ($722K)

Approx. gross sale proceeds $722K

Approx. exercise cost $43K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	19,285	$0.00	$0.00
Exercise	Common Stock	19,285	$2.21	$43K
Sale	Common Stock	9,624	$75.06	$722K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 16,642 shares (Direct)

Footnotes (2)

1. F1. The shares were sold to cover the exercise price and applicable tax withholding obligations in connection with the exercise of the stock options.
2. F2. The stock options were granted on August 1, 2016 and are fully vested.

Key Figures

Options Exercised: 19,285 shares Exercise Price: $2.2100 per share Shares Sold: 9,624 shares +3 more

6 metrics

Options Exercised 19,285 shares Stock option exercise into common stock on June 15, 2026

Exercise Price $2.2100 per share Exercise price for 19,285 stock options converted to common shares

Shares Sold 9,624 shares Common shares sold on June 15, 2026 following option exercise

Sale Price $75.0600 per share Per-share price for 9,624 TransMedics common shares sold

Post-transaction Holdings 16,642 shares Direct common stock holding reported after the transactions

Option Expiration Date 2026-08-01 Expiration date of the exercised stock options granted August 1, 2016

Key Terms

Stock Option (Right to Buy), exercise price, tax withholding obligations, fully vested

4 terms

Stock Option (Right to Buy) financial

"security_title "Stock Option (Right to Buy)" with underlying common stock"

exercise price financial

"conversion_or_exercise_price "2.2100" identified as the exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

tax withholding obligations financial

"shares were sold to cover the exercise price and applicable tax withholding obligations"

fully vested financial

"The stock options were granted on August 1, 2016 and are fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Thomas J. Gunderson report in his Form 4 for TMDX?

Thomas J. Gunderson reported exercising stock options for 19,285 TransMedics (TMDX) common shares at $2.21 per share and selling 9,624 shares at $75.06. After these transactions, he directly holds 16,642 common shares.

How many TransMedics (TMDX) shares did Gunderson sell and at what price?

He sold 9,624 shares of TransMedics common stock at $75.06 per share. A contextual note states that these shares were sold to cover the stock option exercise price and related tax withholding obligations connected to the option exercise.

What stock options did Gunderson exercise in this TMDX Form 4 filing?

Gunderson exercised stock options (right to buy) covering 19,285 TransMedics common shares at an exercise price of $2.21 per share. A contextual note indicates the options were granted on August 1, 2016 and are fully vested.

What is Thomas J. Gunderson’s direct TMDX shareholding after these transactions?

After the reported option exercise and share sale, Gunderson directly holds 16,642 shares of TransMedics common stock. This post-transaction balance is reported as his canonical direct holding in the filing’s position disclosure.

Were Gunderson’s TMDX transactions made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is false, indicating the transactions were not affirmed as made pursuant to a Rule 10b5-1 trading plan. The contextual footnotes describe the purpose of the sale but do not reference any trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/17/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gunderson Thomas J.

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MASSACHUSETTS 01810

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		M		19,285	A	$2.21	26,266	D
Common Stock	06/15/2026		S(1)		9,624	D	$75.06	16,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.21	06/15/2026		M			19,285	(2)	08/01/2026	Common Stock	19,285	$0.00	0	D

Explanation of Responses:

1. The shares were sold to cover the exercise price and applicable tax withholding obligations in connection with the exercise of the stock options.

2. The stock options were granted on August 1, 2016 and are fully vested.

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)